Skip to content

Comparison of Pathadarvyadi churna vati with Tablet metformin and only tablet metformin in the treatment of diebetes Mellitus(Type 2)

A Randomized controlled clinical study for evaluation of adjuvant effect of Pathadarvyadi churna vati with Tablet metformin in the management of Prameha with special reference to diebetes Mellitus Type 2

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/04/018471
Enrollment
60
Registered
2019-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Pathadarvyadichurna vati: Pathadarvyadichurna vati is preapared by vati kalpana and will be given orally 500mg before meal twice a day with luke warm water which includes followup on ev

Sponsors

Prinipal PDEAs college of Ayurveda and Research centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age group between 35 years to 65 years. 2 Cases of both Gender will be included. 3 Patient with fasting blood sugar upto 200 mg% and post prandial blood sugar upto 300 mg%

Exclusion criteria

Exclusion criteria: 1.Insulin Dependent Diabetes Mellitus (IDDM) and those who are under insulin therapy. 2.Patients with acute complications like Hyperglycemic & hypoglycemic coma, Ketoacidosis and related complication and Infections like gangrene. 3.Patients with chronic diabetic complications like Nephropathy, Neuropathy and Retinopathy. 4. Pregnant & lactating women. 5. Patients suffering from all major systemic diseases.

Design outcomes

Primary

MeasureTime frame
To evaluate efficacy of PathaDarvyadi Churna Vati 500 mg two times before meal a day for 3 months as an adjuvant medication to Metformin 500 mg in the management of Prameha with special reference to Diabetes Mellitus type 2 on the basis of BSL and HbA1c values Timepoint: 90 days with follow up on every 15th day

Secondary

MeasureTime frame
1 to study the effect of pathadarvyadi churna vati 2 to study the effect of metformin 3 to observe the adverse effect if anyTimepoint: 90 days

Countries

India

Contacts

Public ContactGaurav rajabhau khawale

PDEAs college of Ayurveda and Research centre

medhamaheshjoshi@gmail.com9881465798

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026